Business · 3 August 2026
AstraZeneca shares dropped over seven percent after merger talks leaked
D Wells via Wikimedia Commons (CC BY-SA 4.0)
Britain's biggest drugmaker is discussing a massive combination with its American counterpart to build a global pharmaceutical titan. Pascal Soriot leads the British firm, which is valued at nearly £196bn before the news emerged. Investors reacted negatively on Monday, sending shares down by more than 7% in early trading.
Reported by Guardian · How we write briefs